Levobetaxolol

Levobetaxolol

Levobetaxolol
Systematic (IUPAC) name
(S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
Clinical data
AHFS/Drugs.com
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
topical (ophthalmic)
Pharmacokinetic data
Biological half-life 20 hours
Identifiers
CAS Registry Number  N
ATC code None
PubChem CID:
IUPHAR/BPS
ChemSpider  YesY
UNII  YesY
ChEBI  YesY
ChEMBL  N
Chemical data
Formula C18H29NO3
Molecular mass 307.427 g/mol
 N   

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Effect

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.

The drug has been associated with bradycardia and hypertension.